Table 1 The comparison of baseline characteristics of patients with and without diabetes.
From: Response to therapy with direct antiviral drugs in HCV-infected patients with diabetes
Parameter | All patients (n = 18968) | Diabetic group (n = 2179) | Non-diabetic group (n = 16789) | p-value |
|---|---|---|---|---|
Age, mean (SD) | 51.2 (14.6) | 61.1 (12.0) | 49.9 (14.5) | < 0.001 (U = 10174088) |
Age ≥ 50, % (n) | 52.6 (9969) | 83.0 (1809) | 48.6 (8180) | < 0.001 (χ2 = 916.2) |
Men/Women, % (n) | 50.2/49.8 (9520/9448) | 53.2/46.8 (1159/1020) | 49.8/50.2 (8361/8428) | 0.003 (χ2=8.9) |
BMI, mean (SD) | 26.2 (4.5) | 28.5 (5.2) | 25.9 (4.3) | < 0.001 (U = 12106021) |
Comorbidities | ||||
Any comorbidities (exluding diabetes), % (n) | 63.7 (12089) | 85.4 (1861) | 60.9 (10228) | < 0.001 (χ2 = 500.2638) |
Obesity, % (n) | 17.5 (3258) | 32.7 (692) | 15.6 (2566) | < 0.001 (χ2=382.4) |
Arterial hypertension, % (n) | 31.5 (5976) | 67.6 (1473) | 26.8 (4503) | < 0.001 (χ2 = 1486.2) |
Autoimmune diseases, % (n) | 2.0 (386) | 2.1 (46) | 2.0 (340) | 0.789 (χ2 = 12.2) |
Non-HCC tumors, % (n) | 2.1 (400) | 2.8 (61) | 2.0 (339) | 0.017 (χ2 = 5.7) |
Renal disease, % (n) | 3.6 (689) | 9.1 (199) | 2.9 (490) | < 0.001 (χ2 = 212.8) |
ALT (IU/L), median (IQR) | 81.4 (73.0) | 89.2 (74.9) | 80.4 (72.7) | < 0.001 (U = 16424357) |
Albumin (g/dL), median (IQR) | 4.1 (0.5) | 3.9 (0.5) | 4.1 (0.5) | p < 0.001 (U = 13667247) |
Bilirubin (mg/dL), median (IQR) | 0.8 (0.8) | 0.9 (0.9) | 0.8 (0.8) | p < 0.001 (U = 16362913) |
Hemoglobin (g/dL), median (IQR) | 14.4 (1.7) | 14.0 (1.8) | 14.4 (1.7) | p < 0.001 (U = 15572149) |
Platelets (*1000/µL), median (IQR) | 197.4 (78.6) | 169.0 (77.5) | 201.0 (78.0) | p < 0.001 (U = 13642364) |
Creatinine (mg/dL), median (IQR) | 0.9 (0.7) | 1.0 (0.7) | 0.9 (0.6) | p < 0.001 (U = 16049900) |
HCV RNA, × 106 IU/mL, median (IQR) | 2.39 (7.14) | 2.89 (6.56) | 2.33 (7.20) | p < 0.001 (U = 16661058) |
